Accéder au contenu
MilliporeSigma

[Effect of nifedipine on organ protection: potential application in patients with aortic aneurysm].

Drugs (2008-01-19)
Ryuichi Morishita, Naruya Tomita
RÉSUMÉ

Useful drug therapy for inhibiting the extension of an aortic aneurysm or promoting its involution has not yet been established. Hypertension is a known risk factor for extension of an aortic aneurysm. However, on a cellular level it is believed that activation of nuclear factor (NF)-kappaB and matrix metalloproteinase (MMP) is involved in the extension of an aortic aneurysm. Nifedipine has been evaluated in a rat model of aortic aneurysm and it was found to inhibit activation of MMP and extension of the aortic aneurysm. Nifedipine also inhibited activation of NF-kappaB and these effects were independent of the antihypertensive effect of the drug. With antihypertensive and vasculoprotective effects and inhibitory actions on activation of NF-kappaB and MMP, nifedipine has potential to be a useful option in the drug treatment of patients with aortic aneurysm.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Nifedipine, ≥98% (HPLC), powder
USP
Nifedipine, United States Pharmacopeia (USP) Reference Standard
Supelco
Nifedipine, Pharmaceutical Secondary Standard; Certified Reference Material
Nifedipine, European Pharmacopoeia (EP) Reference Standard